Selenium in carcinogenesis.
D015073:2-Acetylaminofluorene / Q000037:antagonists & inhibitors; D015127:9,10-Dimethyl-1,2-benzanthracene / Q000037:antagonists & inhibitors; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002945:Cisplatin / Q000009:adverse effects; D004781:Environmental Exposure; D004812:Epidemiologic Methods; D005979:Glutathione Peroxidase / Q000378:metabolism; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D008770:Methylnitrosourea / Q000037:antagonists & inhibitors; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D011639:Public Opinion; D012643:Selenium / Q000097:blood / Q000627:therapeutic use*; D014481:United States
D000975:Antioxidants; D015127:9,10-Dimethyl-1,2-benzanthracene; D008770:Methylnitrosourea; D015073:2-Acetylaminofluorene; D005979:Glutathione Peroxidase; D012643:Selenium; D002945:Cisplatin